Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance.

J Immunother Cancer · 2025 · PMC12699560 · PMID 41381218

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The 5F9-hIgG4 group exhibited significant weight loss after dosing, while anti-CD47-mIgG2a showed a trend of weight reduction at the study end, though not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.